Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
Oudard S, Ratta R, Voog E, Barthelemy P, Thiery-Vuillemin A, Bennamoun M, Hasbini A, Aldabbagh K, Saldana C, Sevin E, Amela E, Von Amsberg G, Houede N, Besson D, Feyerabend S, Boegemann M, Pfister D, Schostak M, Huillard O, Di Fiore F, Quivy A, Lange C, Phan L, Belhouari H, Tran Y, Kotti S, Helissey C. Oudard S, et al. Among authors: bennamoun m. JAMA Oncol. 2023 Dec 1;9(12):1629-1638. doi: 10.1001/jamaoncol.2023.4255. JAMA Oncol. 2023. PMID: 37883073
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
Louvet C, de Gramont A, Bennamoun M, Demuynck B, Varette C, Cady J, Delfau S, Grangé JD, Chazouillères O, Zylberait D, et al. Louvet C, et al. Among authors: bennamoun m. Eur J Cancer. 1992;28(2-3):611-2. doi: 10.1016/s0959-8049(05)80102-9. Eur J Cancer. 1992. PMID: 1591080 No abstract available.
Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S. Thibault C, et al. Among authors: bennamoun m. Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29636272
REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study.
Vauchier C, Auclin E, Barthélémy P, Carril-Ajuria L, Ryckewaert T, Borchiellini D, Castel-Ajgal Z, Bennamoun M, Campedel L, Thiery-Vuillemin A, Coquan E, Crouzet L, Berdah JF, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-Goupil M, Vano YA, Thibault C, Oudard S. Vauchier C, et al. Among authors: bennamoun m. J Oncol. 2022 Feb 18;2022:3449660. doi: 10.1155/2022/3449660. eCollection 2022. J Oncol. 2022. PMID: 35222642 Free PMC article.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-Goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard JC, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun CM, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-Carpentier C, Zucman-Rossi J, Fridman WH, Sautès-Fridman C, Oudard S. Vano YA, et al. Among authors: bennamoun m. Lancet Oncol. 2022 May;23(5):612-624. doi: 10.1016/S1470-2045(22)00128-0. Epub 2022 Apr 4. Lancet Oncol. 2022. PMID: 35390339 Clinical Trial.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Vano YA, Phan L, Gravis G, Korakis I, Schlürmann F, Maillet D, Bennamoun M, Houede N, Topart D, Borchiellini D, Barthelemy P, Ratta R, Ryckewaert T, Hasbini A, Hans S, Emambux S, Cournier S, Braychenko E, Elaidi RT, Oudard S. Vano YA, et al. Among authors: bennamoun m. Int J Cancer. 2022 Oct 15;151(8):1335-1344. doi: 10.1002/ijc.34126. Epub 2022 Jun 6. Int J Cancer. 2022. PMID: 35603906 Free PMC article.
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
Tougeron D, Dahan L, Evesque L, Le Malicot K, El Hajbi F, Aparicio T, Bouché O, Bonichon Lamichhane N, Chibaudel B, Angelergues A, Bodere A, Phelip JM, Mabro M, Kaluzinski L, Petorin C, Breysacher G, Rinaldi Y, Zaanan A, Smith D, Gouttebel MC, Perret C, Etchepare N, Emile JF, Sanfourche I, Di Fiore F, Lepage C, Artru P, Louvet C; PRODIGE 59-FFCD 1707-DURIGAST Investigators/Collaborators. Tougeron D, et al. JAMA Oncol. 2024 Apr 4. doi: 10.1001/jamaoncol.2024.0207. Online ahead of print. JAMA Oncol. 2024. PMID: 38573643
116 results